SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to a combination of factors including its shift to a hybrid infrastructure model with AI GPU hosting, potential short squeeze, and positive sentiment from an ongoing conference. Community members are closely watching for a breakout above key resistance levels, while also acknowledging the risks associated with volatility and dilution. The stock's low float is contributing to significant price swings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending down as investors react to concerns over increased spending on AI infrastructure and growing debt, despite a solid backlog. The community is debating whether the drop is an overreaction or a sign of deeper issues, while analysts are trimming their price targets. Some traders are looking for a bottom while others are anticipating a further decline.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending ahead of its Autonomy and AI Day, where the company is expected to showcase its in-house software and self-driving technology; community chatter revolves around speculation on potential announcements and comparisons to Tesla's approach, particularly regarding lidar; broader discussion includes debate around Rivian's valuation, production capabilities, and long-term strategy in the competitive EV market.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors anticipate earnings, with much of the conversation centered on its potential role in the AI landscape and possible new deals with major tech players like Microsoft. Community members are weighing the potential for a significant post-earnings move, drawing comparisons to both positive and negative reactions from other tech companies like Oracle. Bullish sentiment seems to be fueled by expectations of strong AI revenue growth and the company's existing relationships with Google and Meta.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station is surging amid excitement surrounding its affiliate Gemini Titan securing a CFTC license for regulated prediction markets, potentially positioning the company to compete with platforms like Kalshi and Polymarket. Community members are actively discussing the potential for a short squeeze, speculating on price targets and a possible return to IPO levels. Bullish sentiment is fueled by optimism surrounding the new market opportunities and the view that the license significantly undervalues the stock.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is experiencing volatility, driven by recent data showing a slowdown in November trading volumes and a price target adjustment from analysts. The community is actively debating whether the dip presents a buying opportunity or signals further declines, while also discussing the potential impact of Robinhood's expansion into prediction markets and banking services. Some traders express frustration with the stock's price action, citing manipulation and correlation with Bitcoin's movements.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is trending as community members rally around its potential as the next big meme coin on the Ethereum blockchain, drawing comparisons to Doge and Pepe. The community emphasizes a strong narrative and is actively promoting the token, anticipating significant gains and widespread adoption. With bullish sentiment and increasing momentum, many believe $YEE is poised for substantial growth in the meme-focused crypto market.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending due to a recently announced national retail distribution agreement with Walmart, which is expected to bring its hearing protection products to a wider audience. The community is actively discussing potential short squeezes and debating whether the Walmart news justifies the stock's increased price, while some express concern about potential pullbacks. Analysts' target prices also seem to be fueling conversation around the stock.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending due to upcoming earnings, with the community actively debating whether the report will catalyze a significant price movement. Some traders are pointing to large options positions as a sign of an impending surge, while others remain cautious, citing broader economic concerns and potential tariff impacts. Bullish investors highlight Lululemon's brand strength, international growth potential, and compelling valuation, while bears express concerns about competition and declining sales.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly prostate cancer, after positive trial data, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future!

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -41.56% and -34.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) breached their fiduciary duties to shareholders. If...

BioXcel Therapeutics, Inc. (BTAI) announced on Wednesday that its BXCL501 demonstrated continued effects and consistent benefit with repeat dosing in the treatment of agitation associated with bipolar disorders or schizophrenia in a late-stage trial.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine, marketed by the company as Igalmi. While the primary objective of the trial was to ascertain the safety of the formulation in an at-home setting, the continued effects and consistent benefits observed with repeat dosing in the trial further support the potential of BXCL501 for use in the outpatient setting, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-reports-positive-topline-exploratory">said</a>.Shares of the company rose 3% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> rose from ‘extremely bearish’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘extremely low’ levels.BioXcel <a href="https://stocktwits.com/news-articles/markets/equity/bioxcel-sublingual-film-well-tolerated-in-bipolar-schizophrenia-trial-in-at-home-settings/chsU5sURdl5">reported</a> late last month that the drug was well-tolerated in the study. The company said that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration (FDA) slated for the first quarter of 2026 and aimed at expanding the label for Dexmedetomidine in the at-home setting.“These positive results, along with the safety and tolerability data previously announced, reinforce BXCL501’s potential in the at-home setting where there is substantial unmet need with no FDA-approved options currently available,” said BioXcel CEO Vimal Mehta.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.BTAI stock is down by 40% this year and by 59% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-lower-ahead-of-inflation-data/chwkJpfRduc">Dow Futures Edge Lower As Investors Turn Cautious Ahead Of Inflation Data: ORCL, KLAR, HOOD, GME Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioXcel Stock Shoots Up 3% Pre-Market After Company Announces Positive Efficacy Data For Agitation Drug In Study

The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting. 

Equity

BioXcel Therapeutics, Inc. (BTAI) on Wednesday said that its late-stage trial evaluating the safety of the company’s BXCL501 as a treatment for agitation associated with bipolar disorders or schizophrenia in the at-home setting met its primary goal of being well-tolerated.BXCL501 is an investigational, orally dissolving film formulation of Dexmedetomidine. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.bioxceltherapeutics.com/news-releases/news-release-details/bioxcel-therapeutics-announces-serenity-home-pivotal-phase-3">said</a> that the data from the study will form the basis of a submission to the U.S. Food and Drug Administration slated for the first quarter of 2026 and aimed at expanding the label for its dexmedetomidine sublingual film called Igalmi in the at-home setting.Igalmi is already approved for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in medically supervised settings.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BTAI">BTAI stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:624/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_9_42_20_AM_png_54402b6e8c.webp" alt="BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="624" height="65"><figcaption>BTAI's Sentiment Meter and Message Volume as of 9:42 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user recommended buying the shares of the company.<stembedurl>https://stocktwits.com/Michael17711771/message/626688937</stembedurl>Another user opined that the study results are very promising long term.<stembedurl>https://stocktwits.com/They_call_me_tater_salad/message/626688733</stembedurl>BioXcel said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.“By meeting its primary endpoint, the SERENITY At-Home Pivotal Phase 3 trial reinforces BXCL501’s potential to be safely used at home like it is already used in the previously FDA approved institutional setting. The unmet medical need in the at-home setting is significant with no FDA-approved treatments,” CEO Vimal Mehta said, while adding that the company believes the total addressable market is “significantly larger” than previously reported.The company said that a total of 246 patients were part of the trial, and 2,437 agitation episodes in 208 patients were treated. All patients were able to successfully self-administer the film, and an average of 11.7 agitation episodes were recorded per treated patient.The company said that available data demonstrate that treatment with BXCL501 regularly reduced symptoms of agitation throughout the trial. A greater percentage of patients experiencing mild, moderate, or severe agitation had full resolution of symptoms in the BXCL501 arm compared with placebo. Complete analyses of the full data set are ongoing and will be shared in time, the company said.BTAI stock is down by 24% this year and by 57% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/mannkind-united-therapeutics-expand-agreement-to-develop-second-investigational-molecule-together/chsURMTRdkC">MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

BioXcel’s Sublingual Film Well-Tolerated In Bipolar, Schizophrenia Trial In At-Home Settings, Retail Says Buy Now Or Regret Later

The company said that no discontinuations due to tolerability were observed in the arm of the study that received BXCL501.

BioXcel Therapeutics drew sharp retail-trader attention early Wednesday as the company gears up to release topline results later in the day for its experimental therapy to treat agitation linked to bipolar disorders and schizophrenia outside of clinical settings.The report from its SERENITY At-Home Phase 3 safety trial will reveal detailed effects of BXCL501, marketed as Igalmi, the company's sublingual film formulation of dexmedetomidine. The company plans to hold an investor call and webcast at 8 a.m. ET to discuss the data.The announcement about the release, made late Tuesday, triggered a 19% spike in&nbsp;<a href="https://stocktwits.com/symbol/BTAI">BioXcel's stock</a> after the bell, sending the ticker to the top of trending symbols on Stocktwits, accompanied by a 118% surge in 24-hour message volume. Sentiment, however, was ‘neutral’ as of the last reading.<figure class="image"><img style="aspect-ratio:1310/194;" src="https://news.stocktwits-cdn.com/BTAI_stock_sentiment_and_message_volume_on_Aug_27_png_6d08b1cb22.webp" alt="BTAI stock sentiment and message volume on Aug 27.png" width="1310" height="194"><figcaption>BTAI stock sentiment and message volume on Aug 27 as of 3:30 am ET | source: Stocktwits</figcaption></figure>Last week, BioXcel captured investors' attention after the company<a href="https://stocktwits.com/news-articles/markets/equity/bio-xcel-stock-in-focus-fda-issues-positive-early-feedback-ahead-of-key-meeting-on-expanded-psychiatric-label-1/chsOR5KRdQ1">&nbsp;said</a> the FDA had provided positive preliminary comments for Igalmi.The trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. Over 12 weeks, participants self-administered either 120 mcg of BXCL501, the same dose approved under medical supervision, or a placebo when symptoms arose.The trial tracked adverse events as its primary safety endpoint, while patients or caregivers also provided feedback using a modified global impression of severity scale.Igalmi is also being studied for agitation associated with Alzheimer's dementia, bipolar disorder, and schizophrenia in outpatient and at-home settings. It has received an FDA breakthrough therapy designation for agitation linked to dementia and a fast-track designation for agitation tied to schizophrenia, bipolar disorders, and dementia.BioXcel's stock short interest has also plunged since March, from over 10.6% to 1.8% as of the end of last week, according to Koyfin data.Shares of the company have shed nearly 15% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/firefly-neuroscience-stock-scores-biggest-gain-in-weeks-on-nvidia-brain-platform-boost/chsxnkFRdkQ">Firefly Neuroscience Stock Scores Biggest Gain In Weeks On Nvidia Brain Platform Boost</a>

BioXcel's trial enrolled 200 patients living with bipolar disorder or schizophrenia who experienced agitation episodes despite being on stable treatment. | Representative image via Getty Images

BioXcel Sparks Retail Frenzy As Stock Soars Ahead Of Phase 3 Results For Bipolar, Schizophrenia Drug

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.

All Eyes On BioXcel Stock As Phase 3 Data For Bipolar, Schizophrenia Drug Due Today

Shares surged after hours on Tuesday, making BioXcel the most talked-about stock on Stocktwits, with message volume up 118% in the 24 hours following the announcement.


Retail chatter surged around BioXcel Therapeutics early Monday after the company said it received positive preliminary FDA comments ahead of an&nbsp;Aug. 20&nbsp;meeting to discuss expanding Igalmi’s label for at-home use in agitation tied to bipolar disorder and schizophrenia.The FDA’s remarks focused on aligning with the company over the format and content of the upcoming&nbsp;supplemental new drug application (sNDA)&nbsp;submission. BioXcel said it is evaluating the comments and expects to provide an update following the meeting.&nbsp;Currently, Igalmi is approved for hospital or supervised clinical use, and a green light for outpatient administration would open a new, significantly larger commercial opportunity.The regulatory update comes on the heels of BioXcel completing its Serenity At-Home Phase 3 trial earlier this month, with&nbsp;the&nbsp;last patient visits finalized across 22 U.S. sites.&nbsp;The pivotal study enrolled more than 200 patients and is designed to assess the safety of a 120 mcg self-administered dose of BXCL501 for acute agitation episodes in home settings. Top-line data are expected later this quarter and will form the backbone of the planned sNDA filing.The FDA has previously granted BXCL501 Breakthrough Therapy designation for dementia-related agitation and Fast Track status for schizophrenia, bipolar disorder, and dementia.&nbsp;BioXcel has also received two favorable recommendations from its Data Safety Monitoring Board, supporting the drug’s advancement toward regulatory review.Last Friday, H.C. Wainwright boosted its price target on the stock to $10 from $8 while sticking with a Buy rating, pointing to growing excitement around BXCL501.&nbsp;The brokerage firm called the upcoming Serenity trial readout “low-risk” and expects the company&nbsp;to&nbsp;file for an expanded label by the end of the year, with the FDA potentially signing off in the second half of 2026.On Aug. 6, BioXcel said a new paper in Frontiers in Pharmacology highlighted dexmedetomidine, the key ingredient in BXCL501.The study showed it could significantly influence stress-related behaviors in preclinical models, raising the possibility that the drug’s use might extend beyond calming acute agitation to helping manage longer-term psychiatric conditions.On Stocktwits, retail sentiment for BioXcel was described as ‘extremely bullish’ with ‘extremely high’ message volume, making it the platform’s most trending stock.One user urged that “$BTAI could be pushed over $50 this week” if investors “stick together,” adding that the community had the power to make it happen.&nbsp;<stembedurl>https://stocktwits.com/Eastcoasttrader11/message/625574895</stembedurl>Another user noted that if the Aug. 20 meeting went positively, it would signal that Phase 3 data had already come back strong as expected.<stembedurl>https://stocktwits.com/PejalPapa/message/625574210</stembedurl><a href="https://stocktwits.com/symbol/BTAI">BioXcel’s stock</a> has declined 8.4% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter surged around BioXcel Therapeutics (BTAI) early Monday after the company said it received positive preliminary FDA comments. (Photo credit: Getty Images)

BioXcel Stock In Focus: FDA Issues Positive Early Feedback Ahead Of Key Meeting On Expanded Psychiatric Label 

The update comes as the company wraps up its pivotal Serenity At-Home Phase 3 trial and analysts grow more optimistic on BXCL501’s commercial potential. 

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FDA Rejects CAPR's Cell Therapy BLA for Genetic Disorder, Stock Tanks

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

BioXcel Therapeutics Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

BTAI
BioXcel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BTAI News

BTAIBioXcel Therapeutics Inc